Skip to main content

Table 1 Patient characteristics and mortality

From: Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock

  GCS ≥ 13 GCS <13
Gender (M/F; n) 12/11 21/10
Age (years; mean ± SD) 69 ± 13 72 ± 10
APACHE II score (mean ± SD) 17 ± 4 * 25 ± 7
Baseline SOFA score (mean ± SD) 8 ± 2 * 10 ± 3
Baseline S100B (μg/L; mean ± SEM) 0.70 ± 0.08° 0.96 ± 0.15
ICU mortality (n; %)   
   DrotAA 6 (67) 10 (67)
   No DrotAA 7 (50) 9 (56)
Hospital mortality (n; %)   
   DrotAA 6 (67) 13 (86)
   No DrotAA 10 (71) 12 (75)
  1. * P < 0.05, °P = 0.05 as compared to patients with GCS <13
  2. number and percentage of DrotAA-treated or -untreated patients who died
  3. APACHE: Acute Physiology and Chronic Health Evaluation; DrotAA: drotrecogin alfa (activated); F: female; ICU: intensive care unit; M: male; SOFA: Sequential Organ Failure Assessment